Accuray Incorporated Price & Performance (ARAY)

Analysts have recently upgraded Accuray from a hold to a buy, despite its shares trading near a 12-month low of $1.40. The company’s latest quarterly earnings surpassed expectations, but ongoing volatility and a high debt-to-equity ratio continue to present risks for investors, warranting close monitoring.123

Recent studies presented at the 2025 Radiosurgery Society meeting reinforce the efficacy of Accuray’s CyberKnife system for central nervous system tumors. The data suggest expanded applications and improved patient outcomes, further supporting the company’s reputation for precision radiation therapy technology in both benign and complex cases.45

Accuray’s stock closed at $1.50, continuing a downward trend over the past two weeks and generating multiple sell signals from major technical indicators. Despite some recent analyst optimism, short-term forecasts remain cautious, with the stock considered high-risk due to persistent volatility and weak momentum.67